



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

July 17, 2025

James A. McNulty
Interim Chief Financial Officer
Inhibitor Therapeutics, Inc.
3014 W. Palmira Avenue
Suite 302
Tampa, FL 33629

Re: Inhibitor Therapeutics, Inc.
Form 10-K for the Year Ended December 31, 2024
Filed March 28, 2025
File No. 001-13467

Dear James A. McNulty:

We have reviewed your filing and have the following comment.

Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe this comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this letter, we may have additional comments.

Annual Report on Form 10-K

Item 1. Description of Business, page 3

1. We note your disclosure on page 3 that, on December 12, 2023, you entered into an Exclusive License Agreement with Johns Hopkins University. In future filings, please provide further details about the material terms of this agreement including, but not limited to, the aggregate amount that could be owed to Johns Hopkins University pursuant to the agreement, the aggregate milestone amounts to be paid, and the royalty range and term, as applicable.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 or Chris Edwards at 202-551-6761 if you have questions regarding the comment.

July 17, 2025

Page 2

Sincerely,

Division of Corporation Finance
Office of Life Sciences